Oddity Tech stock rating reiterated at Market Outperform by Citizens

Oddity Tech (NASDAQ:ODD) reported Q3 2025 results modestly above guidance and consensus—revenue $148m vs. $145.4m expected and EPS $0.40 vs. $0.35—alongside EBITDA that beat the high end of guidance by 3%; the company posted 25.8% year‑over‑year revenue growth and a 73.1% gross margin. Analyst firm Citizens reiterated a Market Outperform and an $80 price target (implying >100% upside from the ~$39.57 share price), highlighting Oddity’s commitment to a 20% growth/20% EBITDA-margin framework, the launch of METHODIQ as a new growth lever and a valuation of roughly 10x estimated 2027 EBITDA, even after the stock’s ~50% drop since Q2.

Analysis

Oddity Tech reported Q3 2025 results that modestly beat expectations: revenue of $148.0 million versus $145.44 million expected and EPS of $0.40 versus $0.35 expected, while EBITDA exceeded the high end of guidance by 3% and revenue beat guidance by 1%. The company posted 25.8% year-over-year revenue growth and a 73.1% gross profit margin, metrics that support Citizens’ view that the business model is resilient despite recent share volatility.

Citizens reiterated a Market Outperform and an $80 price target—implying over 100% upside from the cited $39.57 share price—and highlighted management’s commitment to a 20% revenue-growth and 20% EBITDA-margin framework plus the METHODIQ product launch as a new growth lever. The note also references a valuation of roughly 10x estimated 2027 EBITDA, which frames the upside/valuation trade-off for longer-dated investors.

Market reaction is mixed: the stock has declined ~50% since Q2 despite current beats, suggesting investor skepticism or heightened execution risk. Given the moderately positive sentiment and limited immediate market impact score, near-term catalysts to monitor are METHODIQ adoption, next-quarter guidance cadence and margin sustainability; failure to sustain the 20%/20% framework would materially alter the investment case.

Key Decisions for Investors

• Consider building a modest long position on weakness given an $80 analyst target and a ~10x 2027 EBITDA valuation, but size positions conservatively because the stock has already fallen ~50% and execution risk remains
• Monitor the next quarterly guidance and early adoption metrics for METHODIQ and confirm sustained revenue growth and 20%+ EBITDA margins before increasing exposure
• If you hold a position, consider protective hedges or trim into strength to manage downside risk from continued volatility and sentiment shifts
• For short-term traders, expect continued volatility despite moderately positive fundamentals; prefer to wait for clearer confirmation of margin and product trajectory before initiating fresh aggressive long bets